What does Zucara Therapeutics Inc. do?
Zucara Therapeutics Inc. is a diabetes life sciences company that is developing ZT-01, a first-in-class, once-daily therapeutic designed to prevent hypoglycemia in people with type 1 diabetes and insulin-dependent type 2 diabetes by inhibiting somatostatin.
How much did they raise?
The company completed its Series B round with a final closing of $5M, after an initial $20M was raised from strategic investors including Sanofi and The Perceptive Xontogeny Venture Fund. The funding round also saw participation from The T1D Fund: A Breakthrough T1D Venture and other new investors.
What are their plans for the money?
With the funds, Zucara Therapeutics plans to continue its Phase 2a trial evaluating the effect of ZT-01 on nocturnal hypoglycemia events in type 1 diabetes, as well as advance the nonclinical development of a once-weekly version of ZT-01, potentially offering new treatment options for insulin-dependent diabetes patients.
What have they achieved so far?
The company has already demonstrated that ZT-01 can increase the glucagon response in people with type 1 diabetes, an important step towards establishing its efficacy in preventing hypoglycemia.
